Abstract
The healing of gastric ulcer is a complicated process that involves the proliferation of epithelial and endothelial cells and the concerted actions of a wide range of growth factors. Prostaglandins play an important role in ulcer healing. Expression of cyclooxygenase-2 (COX-2) is markedly upregulated around the margins of gastric ulcers and its inhibition leads to a delay of ulcer healing. Several of the growth factors that promote ulcer healing may work in part through COX- 2-dependent mechanisms. Angiogenesis, which is crucial to ulcer healing, is tightly regulated by growth factors. Treatment with selective COX-2 inhibitors appears to alter the balance of serum levels of growth factors, favoring an inhibition of angiogenesis. Given the importance of COX-2 in regulating ulcer healing, caution should be taken in the use of selective inhibitors of COX-2 by patients at risk of ulcer disease.
Keywords: ulcer healing, angiogenesis, cyclooxygenase, prostaglandin, endothelium, platelets
Current Pharmaceutical Design
Title: Mucosal Repair and COX-2 Inhibition
Volume: 9 Issue: 27
Author(s): Rafael F. Perini, Li Ma and John L. Wallace
Affiliation:
Keywords: ulcer healing, angiogenesis, cyclooxygenase, prostaglandin, endothelium, platelets
Abstract: The healing of gastric ulcer is a complicated process that involves the proliferation of epithelial and endothelial cells and the concerted actions of a wide range of growth factors. Prostaglandins play an important role in ulcer healing. Expression of cyclooxygenase-2 (COX-2) is markedly upregulated around the margins of gastric ulcers and its inhibition leads to a delay of ulcer healing. Several of the growth factors that promote ulcer healing may work in part through COX- 2-dependent mechanisms. Angiogenesis, which is crucial to ulcer healing, is tightly regulated by growth factors. Treatment with selective COX-2 inhibitors appears to alter the balance of serum levels of growth factors, favoring an inhibition of angiogenesis. Given the importance of COX-2 in regulating ulcer healing, caution should be taken in the use of selective inhibitors of COX-2 by patients at risk of ulcer disease.
Export Options
About this article
Cite this article as:
Perini F. Rafael, Ma Li and Wallace L. John, Mucosal Repair and COX-2 Inhibition, Current Pharmaceutical Design 2003; 9 (27) . https://dx.doi.org/10.2174/1381612033454027
DOI https://dx.doi.org/10.2174/1381612033454027 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Carbon Nanoparticles in Mongolian Medicine Alleviate Acute Gastric Ulcer Induced by Ethanol by Regulating Fas/FasL Pathway
Current Drug Delivery Oxidative and Non-Oxidative Metabolomics of Ethanol
Current Drug Metabolism The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Proanthocyanidins in Health Care: Current and New Trends
Current Medicinal Chemistry Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics The Role of the Gastrointestinal Microbiota in Colorectal Cancer
Current Pharmaceutical Design Topical Use of Sucralfate in Epithelial Wound Healing: Clinical Evidence and Molecular Mechanisms of Action
Recent Patents on Inflammation & Allergy Drug Discovery Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications
Current Pharmaceutical Design Glucuronides in Anti-Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research